The results from the first randomized, placebo-controlled study for Gilead Sciences Inc.’s remdesivir in China have seemingly disappointed, but some say the repurposed antiviral may still go on to get a regulatory approval for COVID-19.
Originally designed to enroll 237 patients, the study was terminated early due to a lack of participants in Wuhan, the former epicenter of the global outbreak where patients have been decreasing